FDA lifts hold on Intellia trial / Beckers

Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

---

Saturday, March 7, 2026, 12:23 am / permalink 20309 / 2 stories in 4 days

Related Stories

---

• FDA rejects Disc Medicine’s rare-disease drug despite priority review / 18 days
• Axpaxli outperforms Eylea in Phase 3; FDA filing expected / 21 days
• BridgeBio’s dwarfism drug posts positive Phase 3 data, FDA filing on track / 25 days
• FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval / 4 wks
• FDA Accepts Summit Therapeutics' Ivonescimab BLA for EGFR‑Mutant NSCLC / 5 wks
• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
• FDA rejects Corcept’s cortisol modulator triggering setback / 2 months

Related Tags

---

StackHealth Time Machine

---